Stacey Rankin is a pharmacist who is specialized in Oncology in Louisville, Kentucky. Patients can reach her at 13410 Eastpoint Centre Dr Ste 101, Louisville or contact her on 877-662-6633. Active license number of Stacey Rankin is 021517 for Oncology in Kentucky. Stacey Rankin is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Stacey Rankin speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Stacey Rankin
Specialization:
Oncology
Credentials:
PHARMD
Gender:
Female
Location:
13410 Eastpoint Centre Dr Ste 101, Louisville, Kentucky, 40223-4160
Phone:
877-662-6633
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Stacey Rankin are as mentioned below.
NPI Number:
1982205142
NPI Enumeration Date:
04 Nov, 2020
NPI Last Update On:
04 Nov, 2020
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Stacey Rankin are as mentioned below.
Specialization
License Number
State
Status
Oncology
021517
Kentucky
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
31 Morning Side Dr, Shelbyville, Kentucky
Zip:
40065-8199
Phone Number:
530-520-7341
Fax Number:
--
Patients can reach Stacey Rankin at 13410 Eastpoint Centre Dr Ste 101, Louisville, Kentucky or can call on phone at 877-662-6633.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 09 December, 2024.